Apo-Minocycline en es it fr

Apo-Minocycline Brand names, Apo-Minocycline Analogs

Apo-Minocycline Brand Names Mixture

  • No information avaliable

Apo-Minocycline Chemical_Formula


Apo-Minocycline RX_link


Apo-Minocycline fda sheet

Apo-Minocycline FDA

Apo-Minocycline msds (material safety sheet)

Apo-Minocycline MSDS

Apo-Minocycline Synthesis Reference

Boothe, Petisi, U.S. Pat. 3,148,212 (1964)

Apo-Minocycline Molecular Weight

457.477 g/mol

Apo-Minocycline Melting Point

No information avaliable

Apo-Minocycline H2O Solubility

52 mg/mL

Apo-Minocycline State


Apo-Minocycline LogP


Apo-Minocycline Dosage Forms

Capsules; Subgingival (sustained-release); IV injection

Apo-Minocycline Indication

For the treatment of infections caused by susceptible strains of microorganisms, such as Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox and tick fevers caused by Rickettsiae, upper respiratory tract infections caused by Streptococcus pneumoniae and for the treatment of asymptomatic carriers of Neisseria meningitidis.

Apo-Minocycline Pharmacology

Minocycline, the most lipid soluble and most active tetracycline antibiotic, is, like doxycycline, a long-acting tetracycline. Minocycline's effects are related to the inhibition of protein synthesis. Although minocycline's broader spectrum of activity, compared to other members of the group, includes activity against Neisseria meningitidis, its use as a prophylaxis is no longer recomended because of side effects (dizziness and vertigo). Current research is examining the possible neuroprotective effects of minocycline against progression of Huntington's Disease, an inherited neurodegenerative disorder. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging.

Apo-Minocycline Absorption

Rapidly absorbed from the gastrointestinal tract and absorption is not significantly impaired by ingestion of food or milk. Oral bioavailability is 100%.

Apo-Minocycline side effects and Toxicity

Minocycline has been observed to cause a dark discoloration of the thyroid in experimental animals (rats, minipigs, dogs and monkeys). In the rat, chronic treatment with minocycline has resulted in goiter accompanied by elevated radioactive iodine uptake and evidence of thyroid tumor production. Minocycline has also been found to produce thyroid hyperplasia in rats and dogs. LD50=2380 mg/kg (rat, oral), LD50=3600 mg/kg (mouse, oral)

Apo-Minocycline Patient Information

Apo-Minocycline Organisms Affected

Enteric bacteria and other eubacteria